The First CAR-T Drugs Have Left the Gate – Madison.com
Madison.com |
The First CAR–T Drugs Have Left the Gate
Madison.com CAR-T treatments take T cells out of a patient, genetically modify the cells so they’re programmed to attack tumor cells expressing a specific protein, and then infuse them back into the patients to attack the cancerous cells. Both Novartis’ and Kite … |
Motley Fool |
The First CAR-T Drugs Have Left the Gate — The Motley Fool
Motley Fool For all the talk about biotechs being nimble, it’s a big pharma that looks like it’ll be the first company to launch a chimeric antigen receptor T-cell (CAR-T) product. |
Phys.Org |
Scientists expand ability of stem cells to regrow any tissue type
Phys.Org When scientists talk about laboratory stem cells being totipotent or pluripotent, they mean that the cells have the potential, like an embryo, to develop into any type of tissue in the body. What totipotent stem cells can do that pluripotent ones can’t … |
Friedreich’s Ataxia News |
Voyager Therapeutics’ Potential Gene Therapy Program for FA Moving Toward Pre-Clinical Stage
Friedreich’s Ataxia News A previous study showed that gene therapy strategies can have the potential to overcome the frataxin (FXN) deficiency found in Friedreich’s ataxia. Based on advanced viral vectors gene delivery technology, Voyager researchers were able to promote the … |
Scope (blog) |
“No” means “no” in stem cell fates, say Stanford researchers
Scope (blog) Being a young, developmentally impressionable cell is also no picnic. How to choose what developmental path to follow? Should it become a nerve cell, a skin cell, a muscle cell? Now stem cell researcher Marius Wernig, MD, along with postdoctoral … |
Slate Magazine (blog) |
Futurography Newsletter: Synthetic Biology and the Space Race
Slate Magazine (blog) This month, Futurography is focusing on synthetic biology, an emerging field that draws on engineering and computer science principles to reshape the basic stuff of life itself. It’s our final course for the current academic year, and we’re excited to … |